NCT00113360View on ClinicalTrials.gov

RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma

PHASE2CompletedINTERVENTIONAL

Enrollment

67

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

July 31, 2009

Study Completion Date

July 31, 2009

Conditions

Neuroendocrine CarcinomaIslet Cell Carcinoma

Interventions

DRUG

RAD001

Starting dose of 5 or 10 mg by mouth daily.

DRUG

Octreotide Depot

30 mg injection into the muscle of either buttock once every 28 (±7) days.

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Novartis Pharmaceuticals

All Listed Sponsors

collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER